Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes~* BMI 20-45kg/m2 inclusive~Exclusion Criteria:~* females who are pregnant, lactating or within \<6 weeks post-partum~* current symptomatic heart failure (NYHA Class III-IV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- albiglutide weekly injection (Type: EXPERIMENTAL): albiglutide weekly subcutaneous injection
- insulin glargine (Type: ACTIVE_COMPARATOR): insulin glargine daily injection

Based on this trial design, predict the completion outcome and termination type (if applicable).